Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Long-Range Transverse-Momentum Correlations and Radial Flow in Pb-Pb Collisions at the LHC.

Physical review letters·2026

Same author

Comparative evaluation of the effect of application of external manoeuvres with no manoeuvre on glottis view during videolaryngoscopy in patients undergoing elective surgery with the head in neutral position.

Revista espanola de anestesiologia y reanimacion·2026

Same author

Real-World Performance of Sotatercept in PAH Patients With Cardiopulmonary Comorbidities: A Retrospective Single Center Experience.

Pulmonary circulation·2025

Same author

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02 TeV.

Physical review letters·2025

Same author

First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.

Physical review letters·2025

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Optimizing weight control in diabetes: antidiabetic drug selection.

S Kalra¹, B Kalra, Ag Unnikrishnan

¹Bharti Hospital, Karnal.

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy

|March 26, 2011

Summary

Metformin and GLP-1 analogs promote weight loss in type 2 diabetes. DPP-4 inhibitors are weight-neutral, while thiazolidinediones cause weight gain. Insulin detemir aids weight control.

Keywords:

diabetes weight control

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Related Experiment Videos

Last Updated: Jun 3, 2026

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Area of Science:

Endocrinology
Pharmacology

Background:

Weight gain is a common concern in type 2 diabetes management.
Conventional treatments like sulfonylureas may contribute to weight gain.

Purpose of the Study:

To evaluate the impact of various antidiabetic drugs on weight control in type 2 diabetes patients.

Main Methods:

Review of clinical data on antidiabetic medications and their effects on body weight.
Analysis of drug classes including metformin, thiazolidinediones, GLP-1 analogs, DPP-4 inhibitors, and insulin.

Main Results:

Metformin is associated with weight reduction or prevention of weight gain.
GLP-1 analogs (liraglutide, exenatide) promote weight loss.
Thiazolidinediones (pioglitazone, rosiglitazone) are linked to weight gain.
DPP-4 inhibitors are generally weight-neutral.
Insulin therapy results are mixed, with insulin detemir showing weight control benefits.

Conclusions:

Certain antidiabetic drugs offer significant weight management benefits.
Metformin, GLP-1 analogs, and insulin detemir are recommended for patients seeking weight control.
Drug selection should consider individual patient needs for both glycemic and weight management.